Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I purchased a few thousand shares today. Hoping I got a bargain for next week.
Good news for Monday
https://news.yahoo.com/global-deal-cut-oil-output-140900105.html
From the yahoo board
SilverFox10 hours ago
FYI: Potential drug Pfizer utilizing Antares Rescue Pen
I came across a ‘potential’ combination drug device rescue pen that Pfizer may be working on in which they have agreed to partner with ATRS per press release dated back on August 6, 2018. Pfizer has not announced it’s developmental drug at this time but a drug being developed by Zealand's Pharma in which it is developing a rescue pen for hypoglycemia and is currently in Phase 3 trials would qualify as a candidate. Zealand’s drug is “Dasiglucagon” and is being developed to offer a stable ready-to-use rescue treatment for severe hypoglycemia.
All type 1 diabetes patients and the most severely affected type 2 patients depend on insulin injections to maintain blood glucose. Consequently, patients must monitor and adjust their blood glucose levels to remain in proper glycemic control, as both high and low blood glucose may affect their health, both in the short and long term.
Severe hypoglycemia is an acute, life-threatening condition resulting from a critical drop in blood glucose levels associated primarily with insulin therapy and is one of the most feared complications of diabetes treatment. The condition of severe hypoglycemia is most frequently seen in people who inject insulin multiple times per day.
Insulin-dependent diabetics, both type 1 and type 2, can have episodes of severe hypoglycemia, resulting in confusion, loss of consciousness and even death.
With six (6) million or more people across the U.S. using insulin, there's a major need for a treatment for hypoglycemia.
While mild hypoglycemia can be treated by eating or drinking something high in carbohydrates, severe acute episodes require intravenous glucose or an injection of glucagon. Glucagon powder, such as in the GlucaGen HypoKit, requires reconstitution and injection with a syringe. Zealand's approach is a ready-to-use "rescue pen" known as HypoPal.
How common is Diabetes?:
Type 2 diabetes is much more common that type 1. According to the 2017 National Diabetes Statistics Report, there are 30.3 million people in the United States with diabetes. That’s close to 1 in 10 people. Among all these people living with diabetes, 90 to 95 percent have type 2 diabetes.. The percentage of people with diabetes increases with age. Less than 10 percent
of the general population has diabetes, but among those 65 and older, the incidence rate reaches a high of 25.2 percent. Only about 0.18 percent of children under the age of 18 had diabetes in 2015. Men and women get diabetes at roughly the same rate, but incidence rates are higher among certain races and ethnicities. American Indians and Alaskan Natives have the highest prevalence of diabetes among both men and women. The black and Hispanic populations have higher rates of diabetes than non-Hispanic whites.
Less
ReplyReplies (2)10
Thank you very much. You should be working in the investor relations department at MRKR.
Thank you
It's total BS what they are pulling with this clown.
True to form he sold already.
Maciste, I would imagine with a 30% drop that there are margin calls out there.
Gatta, I saw the same date on Yahoo and Ameritrade shows the 13th with a question mark for earnings. If your in the minority on lack of company communication I'm right there with you. This is BS.
Adjusted lost .05 for the quarter.
Yea I saw that.Can we afford to get involved with a company who's stock is at $355 a share and a market cap of 26 billion? Well I guess we can take a wild ass gamble once in a while. Me likes it!
Yea, hopefully Baylor or Mayo will release some information soon. Unfortunately we can't count on the company to let us know anything.
Very low volume
Keep your fingers crossed.
Short interest down 977,599 shares for the 2 weeks ending mid October.
Thanks, much appreciated
What do you figure early 2020 until we hear anything substantial?
OUCH!
Thanks for your insight. You sound like a really cool guy!
Thank you
I'LL drink to that
Sometimes it's hard for people to admit they were outsmarted or were dead wrong.
Another solid quarter for what should be a core holding in many peoples portfolio.
Thank you
"In any event, I believe news will be forth coming that should take us to fair value".
That's the question now, what is fair value?
I guess we are not going to $30 today.
Yea Maciste, sell and go back where you came from! LOL
Found this today:
Cryoport (NASDAQ:CYRX) initiated with Outperform rating and $24 (22% upside) price target at SVB Leerink.
Don't be silly. If we know about this stock, so does the street.
Last sentence in the opening paragraph of the release:
The acquisition is structured as an asset purchase and is expected to be immediately accretive to Cryoport's earnings.
The release said it is accretive.